Considering the upregulation of PARP1 in CML patients' datasets and the upregulation of metabolic pathways in patients expressing high levels of PARP1, we wondered if such a strong induction of DNA damage could result in the PARP-dependent depletion of total cellular NAD+ levels. Here, PARP1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.